Skip to content
Peptide research

PE-22-28

Also known as Spadin Analog · Mini-Spadin
Category
Brain & Cognition
Regulatory status
Not FDA-approved

What it is

A spadin-derived peptide marketed for rapid antidepressant effects by blocking brain TREK-1 channels, giving a ketamine-like mood lift via a different pathway. Evidence is preclinical, from rodent studies, with no human trials and speculative cognitive claims. The headline gap is safety: no human safety data exists, and cell-proliferation and SSRI/SNRI concerns are unresolved. It has no approved use and is sold only as an unregulated research chemical.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Rapid-onset antidepressant activity

    Medium

    Consistent rodent antidepressant-like effects with a clear mechanism, but no human trials yet.

  • Enhanced hippocampal neurogenesis

    Medium

    Two independent rodent studies show increased neurogenesis markers, not yet tested in humans.

  • Increased synaptogenesis and synaptic plasticity

    Medium

    Rodent and cell studies show increased synaptic protein markers, with no human data yet.

Evidence limits

Evidence Level
Preclinical Only

All evidence for PE-22-28 comes from in vitro cell-based assays (patch-clamp electrophysiology on hTREK-1/HEK cells, cortical neuron cultures) and in vivo mouse behavioral models (forced swimming test, tail suspension test, novelty suppressed feeding test). No human clinical trials (Phase 1, 2, or 3) have been published or registered on ClinicalTrials.gov as of March 2026. The broader spadin research program (from which PE-22-28 derives) spans approximately 20 PubMed-indexed publications from 2006-2020 across multiple independent research groups at CNRS/IPMC. The preclinical evidence is consistent: PE-22-28 and spadin show robust TREK-1 inhibition, rapid antidepressant effects, neurogenesis promotion, synaptogenesis enhancement, and BDNF upregulation without cardiac or other systemic side effects. However, the absence of any human data means efficacy, pharmacokinetics, and safety in humans remain entirely unestablished. French patent FR3057266A1 covers PE-22-28 and analogs for depression treatment, indicating commercial development intent.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Concurrent serotonergic medications (SSRIs, SNRIs, MAOIs)

    High

    TREK-1 channel blockade has antidepressant effects. Combined with serotonergic drugs, risk of excessive monoamine activity.

  • Cardiac arrhythmias

    Moderate

    TREK-1 channels are expressed in cardiac tissue. Preclinical data shows no cardiac effects but human data lacking.

General cautions

  • Pregnancy

    Absolute

    No human data. Entirely preclinical — TREK-1 channels play roles in neurodevelopment.

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No established human safety profile

    High
  • Theoretical serotonin syndrome risk with SSRIs/SNRIs

    Theoretical
  • Potential for uncontrolled neurogenesis or cellular proliferation

    Theoretical
  • TREK-1 inhibition and neuroprotection trade-off

    Low
  • Quality and purity concerns: unregulated products sold online vary in purity

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.